Crossmark

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1038/s41598-024-70242-8

Published Online: 2024-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suvarna, Renuka

Shetty, Sahana

Pappachan, Joseph M.
Funding

Funding for this research was provided by:

Manipal Academy of Higher Education, Manipal
License Information

Text and Data Mining valid from 2024-08-26

Version of Record valid from 2024-08-26
More Information

Article History

Received: 24 May 2024

Accepted: 14 August 2024

First Online: 26 August 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below